

**TO**

All Providers, HMOs and Other Managed Care Programs

REGARDING

Revised Procedure Code Descriptions for COVID-19 Vaccines Approved for Members Aged 6 Months Through up to 5 Years

Revised Procedure Code Descriptions for COVID-19 Vaccines Approved for Members Aged 6 Months Through up to 5 Years

Effective for dates of service on and after June 17, 2022, ForwardHealth reimburses providers for the administration of the Moderna and Pfizer COVID-19 vaccines to members aged 6 months–5 years and 6 months–4 years, respectively, following guidance and recommendations by the U.S. Food and Drug Administration, Centers for Disease Control and Prevention, and Centers for Medicare & Medicaid Services (CMS).

When administering a vaccine to children under 6 years old, pharmacists must comply with Wis. Stat. § [450.035\(2c\)](#), which has provisions allowing trained pharmacists to administer vaccines to persons aged 6 years and younger. Providers are reminded that Moderna COVID-19 vaccines are not yet approved for members aged 6–17 years.

The following table contains updated procedure code descriptions for Moderna COVID-19 vaccines for members aged 6 months–5 years to align with CMS guidance.

MODERNA PROCEDURE CODE	DESCRIPTION
91311	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 25 mcg/0.25 mL dosage, for intramuscular use
0111A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 25 mcg/0.25 mL dosage; first dose



MODERNA PROCEDURE CODE	DESCRIPTION
0112A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 25 mcg/0.25 mL dosage; second dose
0113A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 25 mcg/0.25 mL dosage; third dose

The following table contains updated procedure code descriptions for Pfizer COVID-19 vaccines for members aged 6 months–4 years to align with CMS guidance.

PFIZER PROCEDURE CODE	DESCRIPTION
91308	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use
0081A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; first dose
0082A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; second dose
0083A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; third dose

Additional information is available on the federal [Advisory Committee on Immunization Practices webpage](#) and the [Wisconsin Department of Health Services COVID-19 webpage](#).

COVID-19-related ForwardHealth Alerts and Updates are available on the [COVID-19: ForwardHealth News and Resources page](#) of the ForwardHealth Portal.